Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $150,317 | $1,498 | $30,273 |
| - Cash | $63,567 | $70,433 | $75,626 | $83,602 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $79,884 | -$74,128 | -$53,329 |
| Revenue | $0 | $0 | $0 | -$53 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | $0 | $0 | $668 |
| % Margin | – | – | – | -1,260.4% |
| EBITDA | -$9,835 | $0 | $0 | $12,645 |
| % Margin | – | – | – | -23,858.5% |
| Net Income | -$11,345 | -$9,471 | -$8,185 | -$6,065 |
| % Margin | – | – | – | 11,443.4% |
| EPS Diluted | -1.03 | -0.86 | -74.32 | 1.07 |
| % Growth | -19.8% | 98.8% | -7,045.8% | – |
| Operating Cash Flow | -$7,878 | -$11,100 | -$6,768 | -$2,510 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7,878 | -$11,100 | -$6,768 | -$2,510 |